| Su, Liping |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 360 | RoW | SG301 Injection, SG301 placebo, pomalidomide, dexamethasone | Hangzhou Sumgen Biotech Co., Ltd. | Relapsed/Refractory Multiple Myeloma | 03/27 | 03/28 | | |
| Recruiting | 2/3 | 142 | RoW | avatrombopag, Doptelet, Placebo | Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Thrombocytopenia, Stem Cell Transplant Complications | 10/24 | 10/25 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
Z+RCHOP/RDHAP, NCT06255704: A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients |
|
|
| Not yet recruiting | 2 | 23 | RoW | Zanubrutinib and RCHOP/RDHAP | Shanxi Province Cancer Hospital | Mantle Cell Lymphoma | 01/26 | 12/27 | | |
| Not yet recruiting | 2 | 30 | RoW | R-EPOCH in Combination With Ibrutinib | Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd. | Richter Transformation | 08/24 | 08/25 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
NCT04715217: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma |
|
|
| Recruiting | 1/2 | 24 | RoW | CD19-CD22 CAR-T cells, Fluorine dara marina injection, Cyclophosphamide injection | Shanxi Province Cancer Hospital, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Lymphoma, B-Cell | 10/24 | 10/25 | | |
NCT04714593: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia |
|
|
| Recruiting | 1/2 | 24 | RoW | CD19-CD22 CAR-T cells, Fluorine dara marina injection, Cyclophosphamide injection | Shanxi Province Cancer Hospital, Shanghai Ultra-T Immune Therapeutics Co. LTD | Acute Lymphocytic Leukemia， B-Cell | 12/21 | 12/23 | | |
NCT04714827: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 24 | RoW | KQ-2003 CAR-T cells, Fluorine dara marina injection, Cyclophosphamide injection, CD19-BCMA CAR-T Cells | Shanxi Province Cancer Hospital, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Multiple Myeloma | 09/24 | 12/25 | | |
NCT06574568: A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 70 | RoW | YKST02, YKST02 for Injection | Excyte Biopharma Ltd | Relapsed or Refractory Multiple Myeloma | 12/26 | 06/27 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Ma, Liangming |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT06238336: Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours |
|
|
| Recruiting | 2/3 | 30 | RoW | CAR-T cell therapy | Shanxi Bethune Hospital | Hematological Malignancy | 11/25 | 12/25 | | |
| Recruiting | 2/3 | 142 | RoW | avatrombopag, Doptelet, Placebo | Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Thrombocytopenia, Stem Cell Transplant Complications | 10/24 | 10/25 | | |
NCT04725942: Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients |
|
|
| Not yet recruiting | N/A | 360 | RoW | Oral Posaconazole tablets | Institute of Hematology & Blood Diseases Hospital, Shanxi Bethune Hospital, The Second Hospital of Hebei Medical University, Tianjin Medical University Cancer Institute and Hospital | Pulmonary Fungal Infection | 04/23 | 04/23 | | |
